T cell receptor recognizing mutant KRAS peptide–MHC complex (TCR recognizing mutant KRAS peptide–MHC complex (Note: There is no widely accepted short abbreviation specific for a mutant KRAS-recognizing TCR; researchers typically specify the particular TCR clone, e.g., "JDIa41b1" or "4TCR2" when relevant[2][3][5].))

A T cell receptor recognizing mutant KRAS peptide–MHC complex is a highly specific receptor (TCR) engineered or selected from T cells to bind to a peptide derived from a mutated form of KRAS (a common oncogenic driver), when this peptide is presented on the surface of cancer cells by a Class I MHC molecule such as HLA-A*11:01[2][3][5]. This recognition is the basis for targeted T cell therapies that can discriminate between mutant and wild-type KRAS, reducing off-target effects on healthy tissue. Enhanced-affinity TCRs or bispecific TCR-based molecules are under development to increase efficacy, though careful selection and screening is needed to mitigate cross-reactivity with self-antigens[5][6]. The primary therapeutic context is adoptive T cell therapy and targeted biologic drugs for cancers harboring actionable KRAS mutations where the relevant HLA allele is present.

Other names

TCR targeting KRAS neoantigen–MHC complexTCR recognizing KRAS G12V (or G12D)–HLA-A*11:01 complexKRAS-mutant-specific TCRTCR targeting KRAS mutant peptide–MHC complex

Specific recognition of mutated KRAS peptide presented by MHC class I molecules (typically HLA-A*11:01)[2][3][5]. Induces cytotoxic T cell activation and killing of KRAS-mutant cancer cells when engaged by the engineered TCR or TCR-mimetic therapy[3][5][6]. May recruit endogenous T cells via bispecific formats (ImmTACs)[6].